We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management.
- Authors
Fernandes, Maria Gabriela O.; Cruz-Martins, Natália; Machado, José Carlos; Costa, José Luís; Hespanhol, Venceslau
- Abstract
Liquid biopsy (LB) has boosted a remarkable change in the management of cancer patients by contributing to tumour genomic profiling. Plasma circulating cell-free tumour DNA (ctDNA) is the most widely searched tumour-related element for clinical application. Specifically, for patients with lung cancer, LB has revealed valuable to detect the diversity of targetable genomic alterations and to detect and monitor the emergence of resistance mechanisms. Furthermore, its non-invasive nature helps to overcome the difficulty in obtaining tissue samples, offering a comprehensive view about tumour diversity. However, the use of the LB to support diagnostic and therapeutic decisions still needs further clarification. In this sense, this review aims to provide a critical view of the clinical importance of plasma ctDNA analysis, the most widely applied LB, and its limitations while anticipating concepts that will intersect the present and future of LB in non-small cell lung cancer patients.
- Subjects
NON-small-cell lung carcinoma; DNA fingerprinting; CIRCULATING tumor DNA; LUNG cancer; CANCER patients
- Publication
Cancer Cell International, 2021, Vol 21, Issue 1, p1
- ISSN
1475-2867
- Publication type
Article
- DOI
10.1186/s12935-021-02382-0